NCT05283720 2026-03-03A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaGenmabPhase 2 Recruiting496 enrolled
NCT04739813 2026-02-24Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaNational Institutes of Health Clinical Center (CC)Phase 1 Recruiting55 enrolled
NCT05998642 2026-02-12Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS LymphomaCanadian Cancer Trials GroupPhase 2 Recruiting30 enrolled